This November 2017 study, in mice, shows improved insulin response for T2 diabetes when using a patch that responds to glucose levels and injects an insulin-stimulating substance:
This is an interesting study, in my eyes primarily because of the patch technology: it senses glucose levels and administers an insulin-stimulating drug (Exendin-4, chemically close to GLP-1 [= GLP-1 receptor agonist], FDA-approved) when in the presence of high glucose levels.
It is, imho, a really interesting approach to a low-tech closed-loop system for T2s. I am not sure about the drugs and how well they would work for humans (maybe not at all), but the technical approach for the delivery itself is promising in my eyes.
The study is not an easy read. This vulgarized summary on diabetes.co.uk is not very detailed but gets the essentials right:
As a note, my description of how a GLP-1 receptor agonist works is greatly simplified and would need a focused post to be fully accurate. Here is a good intro of them on WebMD: